High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.
about
Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New NomenclatureENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
P2860
High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.
description
2016 nî lūn-bûn
@nan
2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
High clinical and morphologic ...... bulky neuroendocrine tumours.
@ast
High clinical and morphologic ...... bulky neuroendocrine tumours.
@en
type
label
High clinical and morphologic ...... bulky neuroendocrine tumours.
@ast
High clinical and morphologic ...... bulky neuroendocrine tumours.
@en
prefLabel
High clinical and morphologic ...... bulky neuroendocrine tumours.
@ast
High clinical and morphologic ...... bulky neuroendocrine tumours.
@en
P2093
P2860
P50
P1476
High clinical and morphologic ...... r bulky neuroendocrine tumours
@en
P2093
Jason Callahan
Michael Michael
Michael S Hofman
Tim Akhurst
P2860
P2888
P304
P356
10.1007/S00259-016-3527-X
P577
2016-09-27T00:00:00Z